OTCMKTS:NWBO Northwest Biotherapeutics (NWBO) Stock Price, News & Analysis $0.30 0.00 (-0.56%) As of 05/2/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Northwest Biotherapeutics Stock (OTCMKTS:NWBO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get NWBO alerts:Sign Up Key Stats Today's Range$0.30▼$0.3150-Day Range$0.19▼$0.4452-Week Range$0.17▼$0.54Volume2.09 million shsAverage Volume4.03 million shsMarket Capitalization$429.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNorthwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.Read More… Northwest Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreNWBO MarketRank™: Northwest Biotherapeutics scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Northwest Biotherapeutics. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Northwest Biotherapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Northwest Biotherapeutics is -3.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Northwest Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.11% of the float of Northwest Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Northwest Biotherapeutics has recently decreased by 2.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNorthwest Biotherapeutics does not currently pay a dividend.Dividend GrowthNorthwest Biotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.11% of the float of Northwest Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverNorthwest Biotherapeutics has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in Northwest Biotherapeutics has recently decreased by 2.52%, indicating that investor sentiment is improving. News and Social Media0.6 / 5News SentimentN/A Search InterestOnly 4 people have searched for NWBO on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows7 people have added Northwest Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Northwest Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.70% of the stock of Northwest Biotherapeutics is held by insiders.Percentage Held by InstitutionsOnly 0.04% of the stock of Northwest Biotherapeutics is held by institutions.Read more about Northwest Biotherapeutics' insider trading history. Receive NWBO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Northwest Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NWBO Stock News HeadlinesNorthwest Biotherapeutics: A Spike On Their Expected Imminent ApprovalApril 22, 2025 | seekingalpha.comInvestors Watching Two Small-Caps for News on Potential Major Advancements in Cancer TreatmentsJanuary 13, 2025 | msn.comURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “gold analysts” have it all wrong… They tell you to invest in gold ETFs - because the popular mining ETFs will someday catch fire and close the price gap with spot gold. May 5, 2025 | Golden Portfolio (Ad)Northwest Biotherapeutics Announces $5 Million Convertible Note Financing and Standby Facility for Up to $50 Million Additional FinancingDecember 26, 2024 | prnewswire.comNorthwest Biotherapeutics: All Is Not Well With This OneDecember 14, 2024 | seekingalpha.comBehind the Bell: Arcutis BiotherapeuticsNovember 5, 2024 | nasdaq.comNorthwest Registered Agent Review 2024: Features, Pricing & MoreOctober 24, 2024 | forbes.com0K95.IL,0P0000AFQ5,0 (0K95.IL)September 14, 2024 | nz.finance.yahoo.comSee More Headlines NWBO Stock Analysis - Frequently Asked Questions How have NWBO shares performed this year? Northwest Biotherapeutics' stock was trading at $0.2748 at the beginning of the year. Since then, NWBO stock has increased by 9.9% and is now trading at $0.3020. View the best growth stocks for 2025 here. How were Northwest Biotherapeutics' earnings last quarter? Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) posted its earnings results on Monday, March, 31st. The biotechnology company reported ($0.02) EPS for the quarter. The biotechnology company earned $0.23 million during the quarter. How do I buy shares of Northwest Biotherapeutics? Shares of NWBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Northwest Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Northwest Biotherapeutics investors own include Clearside Biomedical (CLSD), Ocular Therapeutix (OCUL), Melinta Therapeutics (MLNT), NVIDIA (NVDA), Intel (INTC), Advanced Micro Devices (AMD) and Meta Platforms (META). Company Calendar Last Earnings3/31/2025Today5/05/2025Next Earnings (Estimated)5/08/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:NWBO Previous SymbolNASDAQ:NWBO CIK1072379 Webwww.nwbio.com Phone(240) 497-9024Fax240-627-4121Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,600,000.00 Net Margins-4,666.29% Pretax Margin-4,356.64% Return on EquityN/A Return on Assets-261.36% Debt Debt-to-Equity RatioN/A Current Ratio0.09 Quick Ratio0.09 Sales & Book Value Annual Sales$1.93 million Price / Sales222.36 Cash FlowN/A Price / Cash FlowN/A Book Value($0.06) per share Price / Book-5.03Miscellaneous Outstanding Shares1,421,073,000Free Float1,237,611,000Market Cap$429.16 million OptionableNot Optionable Beta-0.67 Social Links 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (OTCMKTS:NWBO) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Northwest Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Northwest Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.